NASDAQ:HOLX - Hologic Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $41.32 +0.24 (+0.58 %) (As of 07/19/2018 04:00 PM ET)Previous Close$41.08Today's Range$40.81 - $41.4852-Week Range$35.10 - $45.58Volume1.03 million shsAverage Volume2.39 million shsMarket Capitalization$11.33 billionP/E Ratio20.35Dividend YieldN/ABeta0.82 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts. Receive HOLX News and Ratings via Email Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry X-ray apparatus & tubes Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:HOLX CUSIP43644010 Webwww.hologic.com Phone508-263-2900 Debt Debt-to-Equity Ratio1.13 Current Ratio1.26 Quick Ratio0.98 Price-To-Earnings Trailing P/E Ratio20.35 Forward P/E Ratio18.53 P/E Growth1.96 Sales & Book Value Annual Sales$3.06 billion Price / Sales3.69 Cash Flow$3.6502 per share Price / Cash11.32 Book Value$9.93 per share Price / Book4.16 Profitability EPS (Most Recent Fiscal Year)$2.03 Net Income$755.50 million Net Margins-4.15% Return on Equity20.86% Return on Assets7.51% Miscellaneous Employees6,233 Outstanding Shares273,010,000Market Cap$11,329.96 Hologic (NASDAQ:HOLX) Frequently Asked Questions What is Hologic's stock symbol? Hologic trades on the NASDAQ under the ticker symbol "HOLX." How were Hologic's earnings last quarter? Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.53. The medical equipment provider earned $789.30 million during the quarter, compared to analyst estimates of $781.23 million. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.50 earnings per share. View Hologic's Earnings History. What guidance has Hologic issued on next quarter's earnings? Hologic updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $2.22-2.27 for the period, compared to the Thomson Reuters consensus estimate of $2.26. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.25 billion.Hologic also updated its Q3 guidance to $0.55-0.57 EPS. What price target have analysts set for HOLX? 14 brokers have issued twelve-month price objectives for Hologic's shares. Their predictions range from $39.00 to $52.00. On average, they anticipate Hologic's share price to reach $45.00 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Ratings for Hologic. What is the consensus analysts' recommendation for Hologic? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Hologic stock? Here are some recent quotes from research analysts about Hologic stock: 1. According to Zacks Investment Research, "We are disappointed with the decline in Hologic's revenues at the Diagnostics segment. The blood screening divestiture is also likely to impede growth for the company. Further, the company’s lowering of the revenue guidance for fiscal 2018 on reduced sales expectations from the Cynosure business raises concern. However, Hologic outperformed its industry over the past three months. The company seeing growth across all geographical regions buoys optimism. International revenue was particularly robust fueled by strong contribution from Cynosure acquisition. Buoyed on differentiated products, Breast Health has been performing well. We are upbeat about the recent FDA PMAs for the ThinPrep Integrated Imager and Clarity HD high-resolution 3D imaging and Intelligent 2D imaging technology." (7/3/2018) 2. BTIG Research analysts commented, "in the New Year; Maintain Buy, $17 PT Our thesis is unchanged as SPNE put up solid results in 1Q18. Recall that SPNE has been transitioning the US spinal hardware business from legacy products to newer products that should (and are) growing at a faster pace, namely Mariner and Shoreline. While it has taken a few quarters, SPNE now has ~45% (up from ~24% in 1Q17) of its US spinal implant revenue coming from newer products. Combined with a growing exclusive distributor base, results came in slightly above expectations at $33.2M (+4.0%) relative to BTIG/Consensus of $32.5M/$32.7M respectively. In addition, orthobiologics continues to grow in the MSD from the strength of the portfolio, +5.2% WW, +4.9% US. SPNE is launching multiple products in both categories through FY18 (including a lateral system, Regatta, in 3Q18) while also developing instrumentation that works with navigation access. Collectively, the business continues its positive progression, the portfolio continues to build, and growth should increase to the MSD to HSD in 2H18. While macro spine dynamics remain soft, SPNE is a share taker (even if it is at a smaller scale than others). We maintain our Buy rating and $17 PT." (5/6/2018) 3. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 5/1/18. The number of digital breast tomosynthesis (DBT) units increased by 199 during April which represents a 165.3% Y/ Y increase. DBT unit penetration increased to 31.8% from 31.1% last month and facility penetration increased to 49.6% from 48.1% last month. More importantly, DBT units placements are up 29.4% year-to-date (YTD) in 2018 vs. 2017. Assuming that HOLX is at least holding mammography market share, we believe its Breast Health business could accelerate some in 2018 given the strong YTD US mammography placements. We note that HOLX’s 3D mammography sales are less than 13% of its total sales." (5/1/2018) Are investors shorting Hologic? Hologic saw a decrease in short interest in June. As of June 15th, there was short interest totalling 8,793,455 shares, a decrease of 19.1% from the May 31st total of 10,875,616 shares. Based on an average daily volume of 2,507,848 shares, the short-interest ratio is presently 3.5 days. Currently, 3.2% of the shares of the company are sold short. View Hologic's Current Options Chain. Who are some of Hologic's key competitors? Some companies that are related to Hologic include FRESENIUS SE &/S (FSNUY), Illumina (ILMN), Express Scripts (ESRX), Humana (HUM), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY), Edwards Lifesciences (EW), Fresenius Medical Care AG & Co. (FMS) and Alexion Pharmaceuticals (ALXN). Who are Hologic's key executives? Hologic's management team includes the folowing people: Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 54)Mr. Robert W. McMahon, Chief Financial Officer (Age 49)Mr. John M. Griffin, Gen. Counsel (Age 57)Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 55)Mr. Eric B. Compton, Consultant (Age 53) Has Hologic been receiving favorable news coverage? News headlines about HOLX stock have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a coverage optimism score of 0.04 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 48.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. Who are Hologic's major shareholders? Hologic's stock is owned by a number of of retail and institutional investors. Top institutional investors include American Capital Management Inc. (0.43%), Davis R M Inc. (0.27%), Gateway Investment Advisers LLC (0.14%), Bank of Montreal Can (0.10%), Retirement Systems of Alabama (0.05%) and Thompson Investment Management Inc. (0.03%). Company insiders that own Hologic stock include Allison P Bebo, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic. Which major investors are selling Hologic stock? HOLX stock was sold by a variety of institutional investors in the last quarter, including Davis R M Inc., Municipal Employees Retirement System of Michigan, Hartford Investment Management Co., Central Bank & Trust Co., Jackson Financial Management, Retirement Systems of Alabama, Amalgamated Bank and Webster Bank N. A.. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy and Peter J Valenti III. View Insider Buying and Selling for Hologic. Which major investors are buying Hologic stock? HOLX stock was bought by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Bank of Montreal Can, Nisa Investment Advisors LLC, Reilly Financial Advisors LLC, DnB Asset Management AS, Curbstone Financial Management Corp, Eastern Bank and Ledyard National Bank. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic. How do I buy shares of Hologic? Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Hologic's stock price today? One share of HOLX stock can currently be purchased for approximately $41.32. How big of a company is Hologic? Hologic has a market capitalization of $11.33 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe. How can I contact Hologic? Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected] MarketBeat Community Rating for Hologic (NASDAQ HOLX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 605 (Vote Outperform)Underperform Votes: 422 (Vote Underperform)Total Votes: 1,027MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?